ValyouNewsExploreMeet Val
Finance

Bausch + Lomb Raises 2026 Guidance Again as Vision '27 Plan Pays Off

Seeking Alpha · October 28, 2026

Key takeaways

The Headline Numbers

Bausch + Lomb (BLCO) just bumped up its own 2026 forecast for the third time this year — a pretty strong signal that its turnaround plan, dubbed Vision '27, is working better than even the company expected. The eye-health giant now projects full-year revenue of $5.450 billion to $5.550 billion, with adjusted EBITDA landing between $1.090 billion and $1.140 billion.

That guidance bump came on the back of a genuinely strong Q3 2026. Revenue hit $1.375 billion for the quarter, up 8% in constant currency, while adjusted EBITDA jumped 34% year-over-year. Margins expanded to 23.6%, and free cash flow came in at $178 million — the company's best cash-generation quarter since its 2022 IPO.

Why Every Segment Is Pulling Its Weight

What stands out here isn't just one hot product line — it's that all three of Bausch + Lomb's business segments grew at once. Pharmaceuticals led the way at 11% growth, Surgical followed at 9%, and Vision Care rounded things out at 6%, all on a constant currency basis. For a company that's been working to prove it can execute consistently post-spinoff, broad-based growth like this is exactly the kind of proof point investors want to see.

Interim CEO Thomas Appio called this the fourth straight quarter of delivering on commitments made at the company's Investor Day — a streak that matters because it builds credibility for the Vision '27 strategic plan, the multi-year roadmap management laid out to grow revenue, expand margins, and strengthen the balance sheet.

What's Next: Project Elios

One storyline worth watching: Project Elios, a pipeline initiative currently under FDA review. Chief Medical Officer Yehia Hashad said the project remains on track, with the company still targeting FDA approval by the end of the year, assuming no new issues arise in the review process. An approval here could add another growth driver heading into 2027.

The Bigger Picture

Raising guidance three times in a single year isn't common, and it tells you management has more confidence in its forward visibility than it's shown in previous years. Combined with record cash generation, Bausch + Lomb looks like it's shifting from "story stock" to a company that's actually compounding results quarter after quarter.

Why it matters

For investors and anyone following eye-health and medtech stocks, repeated guidance raises signal real operational momentum, not just optimistic projections. It's a useful case study in how a post-spinoff company builds credibility through consistent execution.

#Bausch + Lomb#BLCO#Earnings#Guidance#Healthcare Stocks

Source: Seeking Alpha

Want deals on what you love?

Val finds local offers matched to your interests — free to start.

Meet Val